In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
After finishing at $118.3 in the prior trading day, Gilead Sciences, Inc (NASDAQ: GILD) closed at $117.85, down -0.38%. In other words, the price has decreased by -$0.38 from its previous closing price. On the day, 6.74 million shares were traded. GILD stock price reached its highest trading level at $121.57 during the session, while it also had its lowest trading level at $117.34.
Ratios:
Our goal is to gain a better understanding of GILD by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 22.42 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.61. For the most recent quarter (mrq), Quick Ratio is recorded 1.15 and its Current Ratio is at 1.32. In the meantime, Its Debt-to-Equity ratio is 1.27 whereas as Long-Term Debt/Eq ratio is at 1.13.
On August 08, 2025, Truist Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $127.
Needham Upgraded its Hold to Buy on July 25, 2025, while the target price for the stock was maintained at $133.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 15 ’25 when Dickinson Andrew D sold 2,500 shares for $118.08 per share. The transaction valued at 295,200 led to the insider holds 157,055 shares of the business.
Mercier Johanna sold 3,000 shares of GILD for $354,240 on Oct 15 ’25. The Chief Commercial Officer now owns 110,193 shares after completing the transaction at $118.08 per share. On Oct 15 ’25, another insider, ANDREW DICKINSON, who serves as the Officer of the company, bought 2,500 shares for $118.08 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GILD now has a Market Capitalization of 146229100544 and an Enterprise Value of 165033099264. As of this moment, Gilead’s Price-to-Earnings (P/E) ratio for their current fiscal year is 23.44, and their Forward P/E ratio for the next fiscal year is 13.67. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.88. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.08 while its Price-to-Book (P/B) ratio in mrq is 7.44. Its current Enterprise Value per Revenue stands at 5.718 whereas that against EBITDA is 11.958.
Stock Price History:
The Beta on a monthly basis for GILD is 0.32, which has changed by 0.35897136 over the last 52 weeks, in comparison to a change of 0.13033986 over the same period for the S&P500. Over the past 52 weeks, GILD has reached a high of $121.83, while it has fallen to a 52-week low of $85.60. The 50-Day Moving Average of the stock is 2.39%, while the 200-Day Moving Average is calculated to be 8.93%.
Shares Statistics:
The stock has traded on average 6.66M shares per day over the past 3-months and 6806980 shares per day over the last 10 days, according to various share statistics. A total of 1.24B shares are outstanding, with a floating share count of 1.24B. Insiders hold about 0.20% of the company’s shares, while institutions hold 88.23% stake in the company. Shares short for GILD as of 1759190400 were 18035549 with a Short Ratio of 2.71, compared to 1756425600 on 17562109. Therefore, it implies a Short% of Shares Outstanding of 18035549 and a Short% of Float of 1.45000005.
Dividends & Splits
In the trailing 12 months, GILD’s forward annual dividend rate was 3.12, compared to 3.14 this year. Against a Trailing Annual Dividend Yield of 0.026373625. The stock’s 5-year Average Dividend Yield is 3.89. The current Payout Ratio is 805.23% for GILD, which recently paid a dividend on 2025-09-15 with an ex-dividend date of 2025-09-15. Stock splits for the company last occurred on 2013-01-28 when the company split stock in a 2:1 ratio.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 20.0 analysts currently analyzing and rating the stock of Gilead Sciences, Inc (GILD).The consensus estimate for the next quarter is $2.07, with high estimates of $2.26 and low estimates of $1.87.
Analysts are recommending an EPS of between $8.35 and $7.74 for the fiscal current year, implying an average EPS of $8.06. EPS for the following year is $8.6, with 27.0 analysts recommending between $9.49 and $6.42.
Revenue Estimates
18 analysts predict $7.45B in revenue for. The current quarter. It ranges from a high estimate of $7.82B to a low estimate of $7.28B. As of. The current estimate, Gilead Sciences, Inc’s year-ago sales were $7.54BFor the next quarter, 18 analysts are estimating revenue of $7.62B. There is a high estimate of $7.91B for the next quarter, whereas the lowest estimate is $7.47B.
A total of 26 analysts have provided revenue estimates for GILD’s current fiscal year. The highest revenue estimate was $29.23B, while the lowest revenue estimate was $28.51B, resulting in an average revenue estimate of $28.83B. In the same quarter a year ago, actual revenue was $28.75BBased on 26 analysts’ estimates, the company’s revenue will be $29.93B in the next fiscal year. The high estimate is $30.97B and the low estimate is $28.67B.
